Genomic Health to Market Epic Sciences’ AR-V7 Liquid Biopsy Test

NEW YORK (GenomeWeb) - Genomic Health and Epic Sciences today announced that they have signed an exclusive agreement under which Genomic Health will commercialize Epic Sciences' AR-V7 liquid biopsy test in the United States.

Test Aids Prostate Cancer Treatment

Wall Street Journal - Genomic Health will commercialize a new screening to influence choice of therapies

Guest Commentary: Back to cancer’s drawing board

By Murali Prahalad of Epic Sciences A curious problem arises for each new precision oncology therapeutic with a companion diagnostic: Many predicted responders exhibit primary resistance.

Epic Sciences' Circulating Tumor Cell Prostate Cancer Test Shows Promise in New JAMA Study

CHICAGO (GenomeWeb) - A new study has demonstrated predictive power of an AR-V7 protein test.

Epic, Avera Ink Deal to Use Liquid Biopsy Platform in Clinical Studies

NEW YORK (GenomeWeb) – Epic Sciences and Avera Medical announced today that they have signed a deal under which the healthcare network will use the company's circulating tumor cell (CTC)-detection and -analysis platform in upcoming clinical studies of precision cancer therapies.

Companion Diagnostics Evolve in the Healthcare Market

ADVANCE for Administrators of the Laboratory - The Epic Sciences platform is featured in a discussion on developments in companion diagnostics.

Never Leave a Cell Behind

DDNEWS- Never leave a cell behind

Utility of CTC Platform in Prostate Cancer MDx

GenomeWeb Daily News “Featured In-Depth”

CAP Accreditation of Epic Sciences Lab

Epic Sciences has recieved accreditation from the College of American Pathologists (CAP). The CAP Laboratory Accreditation Program is recognized by the United States government as being equally or more stringent than the federal inspection program and is designed to specifically ensure the highest standard of care for all laboratory samples.

Oncology’s Future

Xconomy- Oncology's Future Liquid Biopsies and the Heterogeneity of Cancer